FASEB Conference: Genome Engineering: Research and...
CMN Briefs
May. 7, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Cognigenics
Company Type: Therapeutics
Main focus: Non-viral delivery of CRISPR-based therapeutics to central nervous system
Company stage: Pre-clinical
Diseases: Neurodegenerative disorders
Genome-editing tool: CRISPR-Cas
Funding stage: Seed stage
Location: Idaho, USA
Website: https://www.cognigenics.io/
Pipeline:
Partners:
Cognigenics is a pre-clinical-stage biotech that has developed a method for intranasal adeno-associated virus (AAV)-based delivery of CRISPR-Cas reagents. Cognigenics’ delivery modality allows the gene-editing cargo to pass the blood brain barrier and reach the central nervous system to treat neurodegenerative disorders.
